Steven Petrou Selected Research

Generalized Epilepsy

8/2019	Human GABRG2 generalized epilepsy: Increased somatosensory and striatothalamic connectivity.
1/2015	Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy.
1/2014	Low glycaemic index diet reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy.
1/2013	Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy.
11/2012	Glucose transporter 1 deficiency in the idiopathic generalized epilepsies.
9/2008	Developmental impact of a familial GABAA receptor epilepsy mutation.
7/2004	GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies.
4/2003	Channelopathies as a genetic cause of epilepsy.
2/2002	Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven Petrou Research Topics

Disease

42	Epilepsy (Aura) 06/2022 - 02/2002
25	Seizures (Absence Seizure) 12/2021 - 11/2006
12	Febrile Seizures (Febrile Seizure) 05/2015 - 02/2002
9	Generalized Epilepsy 08/2019 - 02/2002
7	Absence Epilepsy (Childhood Absence Epilepsy) 05/2015 - 11/2002
5	Myoclonic Epilepsies (Myoclonic Encephalopathy) 12/2021 - 02/2002
3	Ataxia (Dyssynergia) 09/2021 - 11/2016
3	Brain Diseases (Brain Disorder) 01/2021 - 06/2015
3	Autosomal Dominant Nocturnal Frontal Lobe Epilepsy 01/2018 - 09/2007
3	Partial Epilepsies (Epilepsy, Partial) 01/2015 - 11/2012
3	Generalized Epilepsy with Febrile Seizures Plus 01/2007 - 02/2002
2	Intellectual Disability (Idiocy) 01/2022 - 08/2015
2	Neurodevelopmental Disorders 01/2022 - 01/2018
2	Channelopathies 09/2021 - 04/2003
2	Drug Resistant Epilepsy 01/2018 - 12/2015
2	Hypoglycemia (Reactive Hypoglycemia) 01/2013 - 01/2011
2	Benign Neonatal Epilepsy (Benign Familial Neonatal Convulsions) 06/2007 - 04/2003
1	Autism Spectrum Disorder 01/2022
1	Reperfusion Injury 01/2021
1	CAPOS syndrome 01/2019
1	Fever (Fevers) 05/2017
1	Unverricht-Lundborg Syndrome (Disease, Unverricht) 05/2017
1	Post-Traumatic Epilepsy (Epilepsy, Post Traumatic) 01/2017
1	Gliosis 01/2017
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2017
1	Multiple Sclerosis 01/2017
1	Neuralgia (Stump Neuralgia) 01/2017
1	Brain Injuries (Brain Injury) 01/2017
1	Inhalant Abuse 12/2016
1	Cardiomyopathies (Cardiomyopathy) 09/2016
1	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2015
1	Frontal Lobe Epilepsy (Epilepsy, Supplementary Motor) 08/2015
1	Alternating hemiplegia of childhood 05/2015
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2015

Drug/Important Bio-Agent (IBA)

16	gamma-Aminobutyric Acid (GABA)IBA 08/2019 - 11/2002
12	GABA-A Receptors (GABA(A) Receptor)IBA 05/2015 - 02/2002
9	Sodium Channels (Sodium Channel)IBA 01/2018 - 04/2003
8	Ion Channels (Ion Channel)IBA 01/2018 - 04/2003
6	Pharmaceutical PreparationsIBA 06/2022 - 11/2010
5	Potassium Channels (Potassium Channel)IBA 09/2021 - 04/2003
4	Quinidine (Chinidin)FDA LinkGeneric 10/2018 - 04/2014
4	Anticonvulsants (Antiepileptic Drugs)IBA 12/2016 - 04/2014
4	Carbamazepine (Tegretol)FDA LinkGeneric 01/2015 - 11/2006
3	SodiumIBA 06/2022 - 11/2012
3	Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIBA 01/2020 - 01/2012
3	Glucose (Dextrose)FDA LinkGeneric 12/2018 - 08/2003
3	LigandsIBA 01/2018 - 07/2006
3	Biological ProductsIBA 05/2017 - 07/2006
3	Proteins (Proteins, Gene)FDA Link 12/2016 - 07/2004
3	Aminobutyrates (Aminobutyric Acid)IBA 03/2015 - 01/2011
3	Insulin (Novolin)FDA Link 01/2013 - 08/2003
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2021 - 12/2016
2	Adenosine Triphosphatases (ATPase)IBA 01/2019 - 05/2015
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 03/2013
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 08/2015 - 09/2007
2	Oxcarbazepine (Trileptal)FDA LinkGeneric 01/2015 - 01/2009
2	ezogabine (retigabine)IBA 06/2014 - 04/2014
2	Blood Glucose (Blood Sugar)IBA 01/2013 - 01/2011
2	Proline (L-Proline)FDA Link 01/2012 - 04/2010
2	BenzodiazepinesIBA 01/2010 - 11/2002
1	CannabidiolIBA 06/2022
1	Terpenes (Terpenoids)IBA 06/2022
1	1,2- diarachidonoyl- glycero- 3- phosphocholineIBA 01/2022
1	Antisense OligonucleotidesIBA 12/2021
1	Triglycerides (Triacylglycerol)IBA 12/2021
1	PotassiumIBA 09/2021
1	Acid Sensing Ion ChannelsIBA 01/2021
1	Lamotrigine (Lamictal)FDA LinkGeneric 01/2021
1	CationsIBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2020
1	EnzymesIBA 01/2019
1	Voltage-Gated Sodium ChannelsIBA 01/2018
1	VenomsIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	CytokinesIBA 01/2017
1	A 7 (A-7)IBA 01/2017
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2017
1	Interleukin-1 (Interleukin 1)IBA 01/2017
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2017
1	Purinergic Receptors (Receptors, Purine)IBA 01/2017
1	TolueneIBA 12/2016
1	Phosphotransferases (Kinase)IBA 09/2016
1	CalciumIBA 09/2016
1	ZincIBA 09/2015
1	IonophoresIBA 09/2015
1	Cholinergic Agents (Cholinergics)IBA 08/2015
1	GTP Phosphohydrolases (GTPases)IBA 06/2015
1	GABA Plasma Membrane Transport ProteinsIBA 05/2015
1	human PRRT2 proteinIBA 01/2015
1	eslicarbazepine acetateIBA 01/2015
1	NucleotidesIBA 01/2015
1	10,11- dihydro- 10- hydroxy- 5H- dibenz(b,f)azepine- 5- carboxamideIBA 01/2015

Therapy/Procedure

10	Therapeutics 12/2021 - 01/2012
2	Induced Hyperthermia (Thermotherapy) 12/2021 - 12/2015
2	Precision Medicine 01/2018 - 10/2017
2	Drug Therapy (Chemotherapy) 01/2016 - 11/2010
1	Diet Therapy (Therapy, Diet) 12/2021
1	Aftercare (After-Treatment) 10/2018
1	Intraventricular Infusions 01/2018
1	Electrodes (Electrode) 01/2018